Unreported incidental pulmonary embolism in patients with cancer: Radiologic natural history and risk of recurrent venous thromboembolism and death

Thromb Res. 2023 Apr:224:65-72. doi: 10.1016/j.thromres.2023.02.010. Epub 2023 Feb 21.

Abstract

Purpose: To assess the risk of recurrent venous thromboembolism (VTE) and death in patients with unreported cancer-associated incidental pulmonary embolism (iPE).

Materials and methods: Matched cohort study on cancer patients with a CT study including the chest between 2014-01-01 and 2019-06-30. Studies were reviewed for unreported iPE, and cases were matched with controls without iPE. Cases and controls were followed for one year, with recurrent VTE and death as outcome events.

Results: Of the included 2960 patients, 171 patients had unreported and untreated iPE. While controls had a one-year VTE risk of 8.2 events per 100 person-years, cases with a single subsegmental iPE had a recurrent VTE risk of 20.9 events, and between 52.0 and 72.0 events per 100 person-years for multiple subsegmental iPE and more proximal iPE. In multivariable analysis, multiple subsegmental and more proximal iPE were significantly associated with the risk of recurrent VTE, while single subsegmental iPE was not associated with the risk of recurrent VTE (p = 0.13). In the subgroup of patients (n = 47) with cancer not in the highest Khorana VTE risk category, no metastases and up to three involved vessels, recurrent VTE occurred in two patients (4.7 cases per 100 person-years). There were no significant associations between iPE burden and risk of death.

Conclusion: In cancer patients with unreported iPE, iPE burden was associated with the risk of recurrent VTE. However, having a single subsegmental iPE was not associated with the risk of recurrent VTE. There were no significant associations between iPE burden and risk of death.

Keywords: Artificial intelligence; Neoplasms; Pulmonary embolism; Retrospective studies; Venous thromboembolism.

MeSH terms

  • Anticoagulants
  • Cohort Studies
  • Humans
  • Neoplasms* / complications
  • Pulmonary Embolism* / complications
  • Pulmonary Embolism* / diagnostic imaging
  • Recurrence
  • Venous Thromboembolism* / complications

Substances

  • Anticoagulants